CAR-BIOME
Research type
Research Study
Full title
A Prospective Observational & Translational Study on Microbiome Profiling To Predict The Efficacy of Chimeric Antigen Receptor T-Cell (CAR-T Cell) Therapy In Patients with Haematological Malignancies
IRAS ID
338608
Contact name
Emma Nicholson
Contact email
Sponsor organisation
The Royal Marsden NHS Foundation Trust
Clinicaltrials.gov Identifier
B172, BRC Immunotherapeutics
Duration of Study in the UK
4 years, 0 months, 30 days
Research summary
There is increasing evidence demonstrating that the microbes that naturally live inside the guts, called gut microbiome, plays an important role in the presence of cancerous cells and are believed to affect how our bodies react to cancer treatments. CAR-T cell is a type of treatment that uses immune cells called T cells that are genetically altered in a lab to enable them to locate and destroy cancer cells more effectively. We hope to gain insight into the microbiome changes that are associated with improved outcomes and/or reduced side-effects following CAR-T cell treatment, with a view to undertaking potential microbiome modulation to improve outcomes and/or reduce side-effects for patients.
Patients who have been diagnosed with any type of blood cancer and are planned to receive CAR-T cell treatment at the Royal Marsden NHS Foundation Trust, will be asked to take part. Samples will be collected until 12 months after CAR-T cell treatment and participants will be contacted after 2 years to answer some questions about how they may still be feeling following their CAR-T cell treatment, or about any side-effects they may still be having.REC name
East of England - Cambridge South Research Ethics Committee
REC reference
24/EE/0286
Date of REC Opinion
5 Feb 2025
REC opinion
Further Information Favourable Opinion